Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 9.768
- Book/Share 2.5668
- PB 12.6676
- Debt/Equity 1.9244
- CurrentRatio 1.8751
- ROIC 0.0638
- MktCap 7129593021.0
- FreeCF/Share 0.5811
- PFCF 54.2022
- PE 55.0095
- Debt/Assets 0.5006
- DivYield 0
- ROE 0.2467
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HIMS | Barclays | -- | Overweight | -- | $48 | Dec. 9, 2025 |
| Initiation | HIMS | KeyBanc Capital Markets | -- | Sector Weight | -- | -- | Oct. 21, 2025 |
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers Health: Capitalizing On Healthcare Innovation
Published: January 09, 2026 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health remains a speculative buy for aggressive growth investors, driven by its pivot toward precision medicine and AI-enabled healthcare. Recent volatility stems from regulatory risks, the Novo Nordisk partnership breakup, and shifting GLP-1 compounding regulations impacting revenue and investor sentiment. HIMS's valuation sits between telehealth and AI/genomics peers, with substantial upside if it becomes more like AI/genomics companies but significant downside if risks materialize.
Read More
Hims & Hers Growth Story Has A Lot To Prove In 2026
Published: January 08, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers is down 50% from all-time highs amid fading momentum in their compounded GLP-1 offerings, while new growth vectors are yet to translate into revenue acceleration. Sequential revenue deceleration, margin contraction, and lowered FY25 guidance have pressured Hims stock, but management maintains ambitious 2030 targets. New growth vectors—testosterone, menopause, Labs, and international expansion are promising, yet have not driven meaningful revenue acceleration.
Read More
Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS expands into Canada and the U.K. while revenue and subscribers grow. However, margins and execution raise concerns.
Read More
Hims & Hers: Looking Beyond GLP-1s To The Next Phase Of Global Growth
Published: January 08, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical integration, and a unique personalized offering position HIMS to regain historical growth rates by 2026 and beyond. Management targets substantial margin expansion, aiming for adjusted EBITDA margins of at least 20% by 2030, with marketing spend expected to decrease.
Read More
Hims & Hers Health: Under-Appreciated Upside
Published: January 07, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health is aggressively expanding through new product launches, international markets, and strategic acquisitions, supporting a bullish outlook. HIMS targets $6.5 billion in 2030 revenue, leveraging a subscriber base with significant runway to reach a 10 million target. Management signals potential to exceed long-term targets, reinforced by a $250 million share buyback reflecting confidence in undervalued shares.
Read More
Hims & Hers: A Rare GARP Setup After The Market Reset
Published: January 07, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers is an asset-light platform. Subscriptions, cross-selling, and personalization drive rising ARPU, strong retention, and improving unit economics with structurally low CAC. Growth has normalized but remains ~50%+, driven by weight loss, Hers, diagnostics, and international expansion. Focusing on personalized plans lifts ARPU and retention, improving revenue quality. Margin volatility reflects investments, not pricing pressure. EBITDA margins remain healthy, free cash flow is positive, marketing efficiency is improving, and liquidity exceeds $1.1 billion.
Read More
Hims & Hers: Capitalizing On Robust Subscriber/ARPU Growth - Upgraded Buy Rating
Published: January 07, 2026 by: Seeking Alpha
Sentiment: Positive
HIMS is upgraded to a speculative Buy after the steep correction, with the cheaper valuations offering a much-needed, improved margin of safety. Robust subscription/ARPU growth, international expansion through M&A activities, and strong operating leverage underpin HIMS' long-term revenue and EBITDA growth prospects. Regulatory headwinds from the FDA and new legislation pose near-term risks, but management remains confident in GLP-1 monetization and compliance.
Read More
Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.
Read More
Hims & Hers: A Great Moment To Buy The Dip
Published: January 05, 2026 by: Seeking Alpha
Sentiment: Positive
Hims & Hers remains a "Buy" as recent catalysts, including renewed GLP-1 partnership talks and share buybacks, support a rebound thesis. HIMS boasts a sticky, high-margin customer base, expanding into new specialties and diagnostics, with international growth representing a $1 billion medium-term opportunity. Q3 revenue grew 49% y/y to $599 million, beating expectations, with subscriber growth and rising average revenue per subscriber driving strong fundamentals.
Read More
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.
Read More
Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses
Published: December 30, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty telehealth platform offering prescription medications, mental health support, and personal care products.
Read More
TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI and Hims & Hers are riding healthcare IT growth, but diagnostics scale and consumer demand set different upside paths.
Read More
3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
Read More
Hims & Hers Expands Subscription-Led Care as Platform Engagement Grows
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS deepens its subscription-led model with new care verticals, diagnostics and global expansion to boost retention.
Read More
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
These 5 Stocks Are Set To Dominate 2026
Published: December 19, 2025 by: Seeking Alpha
Sentiment: Positive
My 2025 picks outperformed the S&P 500 by 9.4% and Nasdaq 100 by 5.9%, validating my growth-value approach. Each stock on this list is operating in a different market segment and two are based in Europe, offering geographic diversification. The featured stocks all show significant undervaluation potential based on rather conservative growth scenarios.
Read More
3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Here are some surging MedTech stocks - GMED, TMDX and HIMS - that may face slowing momentum in 2026.
Read More
Hims & Hers Scales Technology-Driven Care as Profitability Evolves
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS scales personalized care, expands globally and invests in technology as it balances growth with evolving profitability.
Read More
Hims & Hers Expands Weight-Management Program to the United Kingdom
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.
Read More
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Read More
Hims & Hers Expands Its Technology-Driven Personalized Virtual Care
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
Read More
Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell?
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Negative
HIMS expands into Canada and Europe while facing regulatory hurdles and execution risks in weight-loss care.
Read More
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugs
Published: December 04, 2025 by: CNBC Television
Sentiment: Positive
Hims & Hers launched in Canada after announcing the company completed its all-cash acquisition of Canadian digital health provider “Livewell”. The deal comes just one month before generic semaglutide weight loss drugs come to market in the country.
Read More
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.
Read More
Hims & Hers shares jump on expansion into Canada
Published: December 04, 2025 by: Proactive Investors
Sentiment: Positive
US-based digital health company Hims & Hers Holdings Inc (NYSE:HIMS) is entering the Canadian market following its acquisition of Livewell, a Canadian telehealth platform focused on weight loss and other wellness services. The move positions Hims & Hers to launch a Canadian weight loss program in 2026, coinciding with the availability of the first generic semaglutide.
Read More
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.
Read More
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.
Read More
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
Published: November 25, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product offerings and logistics, driving subscriber and revenue growth, despite near-term margin compression and increased capital expenditures. The upcoming Zava acquisition and potential regulatory changes could further boost HIMS's international presence and revenue, with DCF-based valuations suggesting significant upside.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Medical - Equipment & Services
- CEO Andrew Dudum
- Employees 1637